ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00370786
Recruitment Status : Completed
First Posted : September 1, 2006
Last Update Posted : July 11, 2008
Sponsor:
Information provided by:
Shahid Beheshti University of Medical Sciences

Brief Summary:
To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc

Condition or disease Intervention/treatment Phase
Choroidal Neovascularization Drug: bevacizumab Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : November 2005
Actual Primary Completion Date : November 2007
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: bevacizumab



Primary Outcome Measures :
  1. Visual acuity [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. central macular thickness [ Time Frame: 6 months ]
  2. leakage in fluorescein angiography [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cases with subfoveal or juxtafoveal CNV due to a non-AMD related cause.

Exclusion Criteria:

  • Evidence of AMD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00370786


Locations
Iran, Islamic Republic of
Hamid Ahmadieh, MD
Tehran, Iran, Islamic Republic of, 16666
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Investigators
Principal Investigator: Hamid Ahmadieh, MD Ophthalmic Research Center of Shaheed Beheshti Medical University

Responsible Party: ophthalmic research center
ClinicalTrials.gov Identifier: NCT00370786     History of Changes
Other Study ID Numbers: 8543
First Posted: September 1, 2006    Key Record Dates
Last Update Posted: July 11, 2008
Last Verified: July 2008

Keywords provided by Shahid Beheshti University of Medical Sciences:
Choroidal neovascularization (CNV)
Bevacizumab
Non AMD
High myopia
angioid streaks
Ocular histoplasmosis
Idiopathic

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents